Burzynski Research Institute (BZYR) Net Income (2010 - 2025)
Burzynski Research Institute (BZYR) posted Net Income of -$190196.0 for Q4 2025, up 27.89% sequentially from -$263755.0 in Q3 2025, and up 31.65% YoY from -$144470.6 in Q4 2024.
Burzynski Research Institute (BZYR) Net Income (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Net Income for 16 years, with the latest figure at -$190196.0 in Q4 2025.
- Quarterly Net Income rose 31.65% year-over-year to -$190196.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was -$1.1 million (up 11.61% YoY) and the FY2025 annual result came in at -$1.4 million, down 3.99% from the prior year.
- Net Income climbed to -$190196.0 in Q4 2025 per BZYR's latest filing, from -$263755.0 in the prior quarter.
- Over five years, Net Income peaked at -$153163.0 in Q1 2021 and troughed at -$433015.0 in Q4 2023.
- A 5-year average of -$263405.0 and a median of -$264265.5 in 2021 frame the typical range for Net Income.
- The sharpest annual moves came in 2021 and 2023: Net Income soared 46.12% in 2021, then slumped 71.4% in 2023.
- Over 5 years, Net Income stood at -$264776.0 in 2021, then gained by 4.58% to -$252639.0 in 2022, then plunged by 71.4% to -$433015.0 in 2023, then surged by 35.74% to -$278269.0 in 2024, then soared by 31.65% to -$190196.0 in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$190196.0, -$263755.0, and -$331451.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | -190,196.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -190,196.00 |
| Aug 31, 2025 | -263,755.00 |
| May 31, 2025 | -331,451.00 |
| Feb 28, 2025 | -292,798.00 |
| Nov 30, 2024 | -278,269.00 |
| Aug 31, 2024 | -292,172.00 |
| May 31, 2024 | -293,352.00 |
| Feb 29, 2024 | -356,080.00 |
| Nov 30, 2023 | -433,015.00 |
| Aug 31, 2023 | -265,973.00 |
| May 31, 2023 | -227,050.00 |
| Feb 28, 2023 | -219,134.00 |
| Nov 30, 2022 | -252,639.00 |
| Aug 31, 2022 | -210,659.00 |
| May 31, 2022 | -231,737.00 |
| Feb 28, 2022 | -170,879.00 |
| Nov 30, 2021 | -264,776.00 |
| Aug 31, 2021 | -224,718.00 |
| May 31, 2021 | -316,283.00 |
| Feb 28, 2021 | -153,163.00 |